JLE

Hépato-Gastro & Oncologie Digestive

MENU

Skin adverse events of anti-tumor necrosing factor agents in IBD Volume 25, issue 6, Juin 2018

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

  • Figure 6

  • Figure 7

  • Figure 8

Tables

Authors
1 CHU de Bordeaux, Service d’hépato-gastroentérologie et oncologie digestive, Centre médico-chirurgical Magellan, 33600 Pessac, France
2 CHU de Bordeaux, Service de dermatologie, Bordeaux, France
* Tirés à part

Cutaneous adverse events are frequent among patients with inflammatory bowel disease (IBD) treated by anti-Tumor Necrosis Factor (TNF)- α agents, concerning 20% of patients. Infections represent half of skin complications, immune-mediated lesions 40% and, neoplastic lesions and local reactions the remaining percentage. Infections that are mostly caused by bacteria or herpes virus reactivation can usually be treated without anti-TNFα withdrawal. Psoriasis and eczema lesions have typical locations, with a palmo-plantar involvement, folds and scalp eruptions. They could be treated in most of cases with topical steroids and vitamin D. Few patients have to stop anti-TNFα and switch to drug with another mode of action. Dermatologic surveillance is now yearly recommended in IBD patients.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License